Neuroprotective Therapy for Stroke and Ischemic Disease

ISBN-13: 9783319832722 / Angielski / Miękka / 2018 / 795 str.

Paul A. Lapchak; John H. Zhang

O autorze

Paul Lapchak is the director of translational neurodegenerative disease research at Cedars-Sinai Medical Center in California. Dr. Lapchak obtained his Ph.D. at McGill University and University of Southern California. His lab focuses on developing new therapeutic approaches to treat different types of stroke as well as experimenting with neuroprotective agents. In addition, his research extends to drug development using the rabbit embolic stroke model and multiple assay methods. Dr. Lapchak is editor-in-chief of the Journal of Neurology & Neurophysiology and associate editor of the journal Translational Stroke Research. With over twenty years of experience and numerous publications, Dr. Lapchak is a leading expert in his field of translational stroke research.

John Zhang is doctor and professor in the departments of Anesthesiology, Neurosurgery, Neurology, and Physiology at the Loma Linda University School of Medicine in California. He obtained his Ph.D. at the University of Alberta, Canada and his MD at Chongqing University of Medical Sciences, China. His lab focuses on hemorrhagic and ischemic stroke, specifically on cerebral vascular biology, neuroprotection, gene therapy, signaling pathways, and apoptosis. Dr. Zhang is on the editorial boards of the journals Surgical Neurology and Neurological Research. Coauthor of countless publications, Dr. Zhang is also a member of several professional societies and participates in current discussions of stroke disease research and neuroprotection.

Blurb

This book is a critical and comprehensive look at current state-of-the-art scientific and translational research being conducted internationally, in both academia and industry; it serves to address new ways to provide effective treatment to victims of ischemic and hemorrhagic stroke and other ischemic diseases. Currently, stroke can be successfully treated through the administration of a thrombolytic, but the therapeutic window is short and many patients are not able to receive treatment. Only about 30% of patients are "cured" by available treatments. Divided into five sections, the proposed volume explores historical and novel neuroprotection mechanisms and targets, new and combination therapies, as well as clinical trial design for some of the most recent bench-side research.